Here, we describe a new model for XPC activation of NER where the off-rate of XPC from the lesion site, particularly in the case of clustered lesions, is the rate-limiting step of NER, and propose applying this finding to design a more efficiently targeted approach to cancer therapy. Here, XPC is linked to cancer.